XML 72 R39.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaborative and Other Relationships (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat |  | $ | 33.9 |  |  | $ | 68.6 |  |  | $ | 77.5 |  |  | $ | 136.6 |
Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income |  | 17.0 |  |  | 34.3 |  |  | 38.7 |  |  | 68.3 |
Total sales and marketing expense incurred by the collaboration |  | 1.4 |  |  | nm |  |  | 6.3 |  |  | nm |
Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 0.7 |  |  | nm |  |  | 3.2 |  |  | nm |
Summary of Activity Related to Aducanumab Collaboration | A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:
|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Total aducanumab development expense |  | $ | 35.9 |  |  | $ | 3.2 |  |  | $ | 55.0 |  |  | $ | 165.8 |
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income |  | 19.7 |  |  | 1.7 |  |  | 30.3 |  |  | 91.2 |
Total aducanumab sales and marketing expense |  | 45.2 |  |  | 0.2 |  |  | 67.9 |  |  | 21.2 |
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 25.2 |  |  | 0.1 |  |  | 37.5 |  |  | 11.7 |
Total aducanumab collaboration third party milestone expense |  | 75.0 |  |  | — |  |  | 75.0 |  |  | — |
Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income |  | 33.8 |  |  | — |  |  | 33.8 |  |  | — |

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration